Inivata Highlights New Clinical Data on InVision™ ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that new clinical data from its collaboration with Dana-Farber Cancer Institute will be presented at the World Conference on Lung Cancer (WCLC).
The study involved a blind retrospective evaluation of Inivata’s InVision ctDNA liquid biopsy analysis to characterize and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib.
Inivata’s technology was shown to detect a full range of genotypes, including gene rearrangements, with an exquisite sensitivity and a high specificity. It was able to detect ALK and ROS1 fusions with high sensitivity, the first time this has been shown using amplicon sequencing. As published previously, there was excellent concordance with droplet digital PCR (ddPCR).
The data will be presented by first author Dr. Nicolas Guibert at 09:30 on Wednesday 18 October in the Biology/Pathology Poster Session in Exhibit Hall B+C.
Poster (P3.02-014): Amplicon-based next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) for detection of driver and resistance mutations in advanced NSCLC.
Commenting on the data, Geoffrey Oxnard, MD, thoracic oncologist and lung cancer researcher at Dana-Farber Cancer Institute, said:
“These data show InVision is able to accurately deliver actionable information to clinicians about a range of genetic alterations and, in particular, its potential to inform the treatment of drug resistance. We look forward to further exploring this assay and its potential to impact patient outcomes.”
Clive Morris, Chief Medical Officer of Inivata, said:
“This is the first time an amplicon based approach to next generation sequencing has been able to detect a full range of targetable genotypes in NSCLC, including ALK and ROS1 fusions. The study also provided further evidence of our platform’s exceptional sensitivity. The breadth of our panel and the sensitivity of InVision is a powerful combination and we continue to add to the body of evidence supporting its clinical utility.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.